Hypofibrinogenemia induced by argatroban combined with urokinase
10.3760/cma.j.cn114015-20220309-00194
- VernacularTitle:阿加曲班与尿激酶联用致低纤维蛋白原血症
- Author:
Shengye LIU
1
;
Nianting GAO
;
Xin'an WU
;
Boxia LI
Author Information
1. 兰州大学第一医院介入医学科，兰州 730000
- Publication Type:Journal Article
- Keywords:
Venous thrombosis;
Hypofibrinemia;
Argatroban;
Urokinase
- From:
Adverse Drug Reactions Journal
2022;24(11):609-611
- CountryChina
- Language:Chinese
-
Abstract:
A 64-year-old male patient underwent diagnostic imaging of lower extremity venography plus inferior vena cava angiography due to deep vein thrombosis of lower extremity. Nadroparin calcium anticoagulation was given for 3 days before the operation, and heparin sodium anticoagulation was given after the operation. On the 3rd day of the operation, the coagulation function test showed fibrinogen (FIB) 2.78 g/L, activated partial thromboplastin time (APTT) 26.4 s. Continuous intravenous pumping of argatroban 1.5 μg/ (kg·min) (22 hours daily) and intravenously pumping of urokinase 600 000 U (lasting 2 hours) were given. On the 4th day of operation, the coagulation function test showed FIB 0.1 g/L and APTT 94.7 s. Considering the possible relation to drugs, urokinase was stopped, the dose of argatroban was reduced to 1.0 μg/(kg·min), and human fibrinogen was added. On the 5th day of operation, the coagulation function test showed FIB 0.49 g/L and APTT 51.2 s, and argatroban was stopped. On the 8th day of operation, the coagulation function test showed FIB 1.30 g/L and APTT 31.8 s, and fresh frozen plasma 750 ml was given twice daily by intravenous infusion. On the 11th day of operation, the coagulation function test showed FIB 2.40 g/L and APTT 28.3 s.
